Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety of sodium phenylbutyrate (NaPB) treatment
in subjects with amyotrophic lateral sclerosis (ALS) and the ability to take this medication
without major side effects.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development